Online citations, reference lists, and bibliographies.

Long‐term Results Of Cytoreductive Surgery For Advanced And Recurrent Epithelial Ovarian Cancers And Papillary Serous Carcinoma Of The Peritoneum

M. Look, D. Chang, P. Sugarbaker
Published 2003 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The aim of this study was to review the long-term results of cytoreductive surgery in the treatment of advanced primary and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum. Our goal was to identify clinical factors by which to select patients likely to benefit from a comprehensive management plan. Clinical data of 28 females who underwent surgery were retrieved from a prospective database. Major cytoreductive procedures were possible in 25 patients. Heated intraoperative or early postoperative intraperitoneal chemotherapy was also used where appropriate. The median follow-up after cytoreduction was 26.9 months. The overall median survival after cytoreduction was 45.8 months. The prognostic indicators associated with a statistically significant impact on survival were the Prior Surgery Score (P < 0.001), the Completeness of Cytoreduction Score (P = 0.037) and response to chemotherapy prior to surgery (P = 0.012). Our findings suggest that cytoreductive surgery can be effective when combined with perioperative intraperitoneal chemotherapy. Results can be improved by excluding cases where completeness of cytoreduction seems unlikely. Extensive prior surgery without the protection of adjunctive intraperitoneal chemotherapy is associated with a poor prognosis. This may be due to disruption of anatomic planes leading to deep abdominal and pelvic dissemination intractable to further treatment.
This paper references
10.1002/1097-0142(19900915)66:6<1091::AID-CNCR2820660602>3.0.CO;2-F
Papillary serous carcinoma of the peritoneum. A review of 33 cases treated with platin‐based chemotherapy
D. Ransom (1990)
Cytoreductive surgery for stage IV epithelial ovarian cancer.
R. Zang (1999)
10.1111/j.1471-0528.1994.tb13080.x
Intervention debulking surgery in advanced epithelial ovarian cancer
C. Redman (1994)
10.1093/JJCO/HYE088
Review of a personal experience in the management of carcinomatosis and sarcomatosis.
P. Sugarbaker (2001)
10.1002/CNCR.2820710205
Ovarian cancer: Age contrasts in incidence, histology, disease stage at diagnosis, and mortality
R. Yancik (1993)
Ovarian and endometrial cancers.
J. Mant (1994)
Ovarian and endometrial cancers. Cancer Survey Trends Cancer Incidence Mortality 1994;9:287—307
Mant JWF (1994)
10.1038/bjc.1981.243
Clinical Gynaecologic Oncology
R. Hunter (1981)
10.1016/0090-8258(91)90335-3
Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer.
J. H. Jacob (1991)
10.1053/BEOG.2002.0302
Interval debulking surgery in advanced epithelial ovarian cancer.
S. Pecorelli (2002)
10.1053/EJSO.2000.1007
Impact of secondary cytoreductive surgery on survival of patients with advanced epithelial ovarian cancer.
R. Zang (2000)
10.1002/1097-0142(19940715)74:2<656::AID-CNCR2820740218>3.0.CO;2-6
Long term survival by cytoreductive surgery to less than 1 cm, induction weekly cisplatin and monthly cisplatin, doxorubicin, and cyclophosphaide therapy in advanced ovarian adenocarcinoma
T. Baker (1994)
10.1056/NEJM199503093321002
The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer.
M. V. D. van der Burg (1995)
THE EFFECT OF DEBULKING SURGERY AFTER INDUCTION CHEMOTHERAPY ON THE PROGNOSIS IN ADVANCED EPITHELIAL OVARIAN CANCER
Aria (2001)
10.1002/(SICI)1098-2388(199804/05)14:3<254::AID-SSU10>3.0.CO;2-U
Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis.
P. Sugarbaker (1998)
Peritoneal carcinomatosis. features of dissemination
M Deraco (1999)
Current methodologies for clinical assessment of patients with peritoneal carcinomatosis
P Jacquet (1996)
Management of Peritoneal Surface Malignancy Using Intraperitoneal Chemotherapy and Cytoreductive Surgery. A Manual for Physicians and Nurses
PH Sugarbaker (1998)
10.1002/1097-0142(20010701)92:1<71::AID-CNCR1293>3.0.CO;2-9
Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy
D. Elias (2001)
10.1006/gyno.1995.1099
Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response.
L. Vaccarello (1995)
Cytoreductive surgery for patients with stage IV epithelial ovarian cancer
RY Zang (1999)
10.1146/annurev.me.32.020181.002355
The natural history and treatment of ovarian cancer.
D. Longo (1981)
Papillary serous adenocarcinoma of the peritoneum
DT Ransom (1990)
10.1159/000066027
Title Pages / Contents
A. L. Barlow (2002)
10.1002/(SICI)1097-0142(20000101)88:1<144::AID-CNCR20>3.0.CO;2-X
The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma
S. Eisenkop (2000)



This paper is referenced by
10.1016/j.ejso.2009.03.004
Cytoreductive surgery and modified heated intraoperative intraperitoneal chemotherapy (HIPEC) for advanced and recurrent ovarian cancer -- 12-year single center experience.
M. Pavlov (2009)
10.17925/OHR.2006.00.02.30
A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma.
T. Yan (2007)
10.1007/s13193-016-0518-0
Preoperative Assessment of Cancer Patients with Peritoneal Metastases for Complete Cytoreduction
P. Sugarbaker (2016)
10.1093/ANNONC/MDL428
A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma
T. Yan (2007)
10.4081/joper.2017.42
Extra-peritoneal hysteroannessiectomy with eventual concomitant en bloc rectal resection and cytoreductive surgery in epithelial ovarian cancer (and other peritoneal surface malignancies): technical details
Luigi Frigerio (2017)
10.3748/WJG.14.1159
Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis.
Hassan-Alaa-Hammed Al-Shammaa (2008)
10.5772/48155
Abdominal Advanced Oncologic Surgery
Enrico Maria Pasqual (2012)
10.1007/2-287-30921-7_25
La chimiothérapie intrapéritonéale avec hyperthermie
O. Gléhen (2006)
Educational Review Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Surface Malignancy: Current Status and Future Directions
J. Stewart (2005)
10.1007/978-3-211-48613-9_26
Primäre und sekundäre peritoneale Tumoren
P. Piso (2008)
10.1016/j.ygyno.2008.08.033
Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis.
R. Bristow (2009)
10.1177/030089161009600306
Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy in Recurrent Ovarian Cancer
Antonios-Apostolos K Tentes (2010)
10.1002/jso.21053
Consensus statement on the loco regional treatment of colorectal cancer with peritoneal dissemination.
J. Esquivel (2008)
10.1007/978-1-59745-195-6
Intraperitoneal cancer therapy
C. Helm (2007)
10.1007/s12094-013-1053-x
Cytoreductive surgery and intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis from colorectal origin
F. Losa (2013)
10.2217/THY.09.90
Role of cytoreductive surgery in recurrent ovarian cancer
A. Fagotti (2010)
10.1002/bjs.5427
Cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal mucinous neoplasms
T. Yan (2006)
10.1016/J.GYOBFE.2011.11.002
CHIP et cancer de l’ovaire : en finir avec les préjugés
Naoual Bakrin (2012)
"METÁSTASIS PERITONEAL DE CÁNCER GASTROINTESTINAL: BREVE HISTORIA"
Paul H Sugarbaker (2014)
10.1016/j.soc.2012.07.007
Current status and future directions of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer.
C. William Helm (2012)
10.1007/978-88-470-5711-1_21
Other primary peritoneal surface malignancies
P. Sammartino (2015)
10.1016/j.ygyno.2020.03.034
Oncologic outcomes and morbidity following heated intraperitoneal chemotherapy at cytoreductive surgery for primary epithelial ovarian cancer: A systematic review and meta-analysis.
Geneviève Bouchard-Fortier (2020)
10.1245/ASO.2006.02.016
Surgical and Chemotherapy Treatment Outcomes of Goblet Cell Carcinoid: A Tertiary Cancer Center Experience
T. H. Pham (2006)
10.1002/jso.21083
Hyperthermic intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer.
C. Helm (2008)
Primary peritoneal adenocarcinoma causes pleural effusion
M. Shameem (2010)
10.1016/j.gyobfe.2011.11.002
[HIPEC and ovarian carcinoma: base judgment on evidence].
Naoual Bakrin (2012)
Hyperthermic intraperitoneal chemotherapy ( HIPEC ) in optimally cytoreduced peritoneal carcinomatosis of gynecology origin : Does it provide survival advantage ?
E. Bree (2010)
10.5772/26816
Combined Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for the Treatment of Advanced Ovarian Cancer
A. Tentes (2012)
10.1111/j.1471-0528.2011.03207.x
Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi‐institutional study
M. Deraco (2012)
10.1016/j.ejogrb.2011.01.006
Protective effect of intra-peritoneal epinephrine on postoperative renal function after cisplatin-based intra-peritoneal intra-operative chemotherapy.
S. Pili-Floury (2011)
10.2217/17455057.2.1.127
Update on the Treatment of Recurrent Ovarian Cancer
G. Eltabbakh (2006)
10.1016/J.SOC.2007.04.015
Cytoreductive surgery for peritoneal malignancies--development of standards of care for the community.
J. Esquivel (2007)
See more
Semantic Scholar Logo Some data provided by SemanticScholar